TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20968017
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy via the LGN‐222 quartz installation
Study: 29889239
Drug: Artesunate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (2 mg/kg/day for 5 days)
Study: 29889239
Drug: Chloroquine-primaquine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine-primaquine (0.5 mg/kg/day for 14 days)
Study: 24378018
Drug: RDT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDT and drugs stock-out
Study: 20881066
Drug: Betahistine 48
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 48 mg/d
Study: 20881066
Drug: Betahistine 96
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 96 mg/d
Study: 20881066
Drug: Betahistine 144
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine 144 mg/d
Study: 20881066
Drug: Betahistine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (all doses)
Study: 10745254
Drug: G-CSF (D5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (D5 to D14)
Study: 10745254
Drug: GM-CSF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF plus G-CSF (D5-D14 and D10-D14 respectively)
Study: 8694202
Drug: Hydroxyethylstarch solution
Normalized name: hydroxyethylstarch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylstarch solution 10% (n=15)
Study: 8694202
Drug: Pentoxifylline continuously
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline continuously (1.2 mg.kg-1.h-1) (n=15)
Study: 1286500
Drug: Flumazenil (0.84
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.84 mg IV, range: 0.2 mg to 1 mg)
Study: 26787366
Drug: Citrus aurantium
Normalized name: Citrus aurantium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus aurantium essential oil through inhalation
Study: 10475411
Drug: Antegrade/retrograde cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antegrade/retrograde cold blood cardioplegia with topical cooling (group II, n = 40)
Study: 10475411
Drug: Antegrade crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antegrade crystalloid cardioplegia with topical cooling (group III, n = 41)
Study: 8622020
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (FAC: fluorouracil 600 mg/m2, doxorubicin 50 mg/m2, cyclophosphamide 600 mg/m2)
Study: 27743126
Drug: 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg midazolam (Midazolam Group)
Study: 19237920
Drug: Transfusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion of packed red blood cells at thresholds of 8, 9, or 10 g/dL
Study: 15024332
Drug: Etidronate 200
Normalized name: etidronate 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 200 mg/day for 2 weeks, then 9-week intermission, followed by 2 weeks of etidronate
Study: 8986484
Drug: Routine chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine chest physiotherapy (RCP) combined with oxygen administration via nasal cannula for 10 min
Study: 6432119
Drug: Diuretic (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (25 mg chlorthalidone)
Study: 6432119
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker (200 mg metoprolol)
Study: 6432119
Drug: Combined agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined agent (chlorthalidone + metoprolol)
Study: 29637714
Drug: C1 esterase
Normalized name: C1 esterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 esterase inhibitor (C1INH) 50 U/kg
Study: 27554088
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 200 mg intravenous ibuprofen
Study: 27554088
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 mg intravenous ibuprofen
Study: 27554088
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 800 mg intravenous ibuprofen
Study: 27554088
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 400 mg intravenous ibuprofen (four times per day)
Study: 20089547
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no changes in drug therapy)
Study: 18652103
Drug: Ephedrine IV
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine IV (10 mg)
Study: 10486792
Drug: Continuous CEE
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous CEE medication (0.625 mg daily) with cyclical supplementation of 5 mg/day of medrogestone acetate for 24 weeks
Study: 8942409
Drug: High-selenium group
Normalized name: HIGH SELENIUM YEAST
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-selenium group (n = 7) received selenate-fortified formulas (0.36 mumol Se/L for preterm, 0.22 mumol Se/L for full-term)
Study: 8942409
Drug: Low-selenium group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-selenium group (n = 10) received non-selenium-fortified formulas (0.12 mumol Se/L for preterm, 0.11 mumol Se/L for full-term)
Study: 26965712
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation enriched with EPA, arginine, and nucleotides before the operation (group IN)
Study: 11792923
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg twice daily for 3 weeks
Study: 11792923
Drug: Nimodipine and
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine and Placebo (regardless of initial treatment)
Study: 7554973
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive containing ethinylestradiol and gestodene (EE/GSD)
Study: 7554973
Drug: Monophasic formulation
Normalized name: Monobasic Potassium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic formulation containing 35 micrograms ethinylestradiol and 250 micrograms norgestimate (EE/NGM)
Study: 17190936
Drug: Estradiol gel
Normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol gel
Study: 27717999
Drug: Dabigatran EM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran EM with bosutinib (100 mg)
Study: 25073669
Drug: 750 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/day of biphenyl dimethyl dicarboxylate (DDB)
Study: 25073669
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day of ursodeoxycholic acid (UDCA)
Study: 22186979
Drug: HZT-501 (ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZT-501 (ibuprofen 800 mg + double-dose famotidine)
Study: 22186979
Drug: Ibuprofen alone
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen alone (800 mg)
Study: 16860964
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1-3
Study: 16860964
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group information based on British Medical Journal 'Best Treatments'
Study: 12534408
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole (n = 26)
Study: 12534408
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pantoprazole (n = 24)
Study: 10650302
Drug: Estrogen/progestin replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen/progestin replacement therapy
Study: 9023640
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg and amoxycillin 1000 mg twice daily for 14 days
Study: 9023640
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg and placebo twice daily for 14 days
Study: 25566817
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 or 50 mg for 6 months)
Study: 24059992
Drug: TwHF (1‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TwHF (1‐2 mg·kg⁻¹·d⁻¹)
Study: 24059992
Drug: Irbesartan (150‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150‐300 mg/d)
Study: 24059992
Drug: TwHF combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: TwHF combined with irbesartan (TwHF 1‐2 mg·kg⁻¹·d⁻¹ + irbesartan 150‐300 mg/d)
Study: 21716965
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of implants following the Columbus Bridge Protocol (4 to 6 implants loaded within 24 hours)
Study: 21716965
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of implants following the ad modum Branemark protocol (6 to 9 implants loaded a mean 8.75 months after surgery)
Study: 16446006
Drug: Prototype formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype formulation of metoprolol succinate
Study: 16446006
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation Beloc-zok
Study: 11447769
Drug: Intravenous 2
Normalized name: Premarin Intravenous 25 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 2 mg tropisetron (single injection)
Study: 11447769
Drug: Intravenous 2
Normalized name: Premarin Intravenous 25 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 2 mg tropisetron (daily for 5 days)
Study: 11447769
Drug: Peroral daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroral daily treatment with 5 mg tropisetron
Study: 9625105
Drug: 8.7 mg
Normalized name: menthol 8.7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.7 mg every 2 weeks (group A)
Study: 9625105
Drug: 29.7 mg
Normalized name: vitamin C 75 MG / ferrous fumarate 90 MG (iron 29.7 MG) Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 29.7 mg every month (group B)
Study: 9625105
Drug: 148.2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 148.2 mg every 3 months (group C)
Study: 9625105
Drug: 382 mg
Normalized name: carbenicillin 382 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 382 mg every 6 months (group D)
Study: 9625105
Drug: 993 mg
Normalized name: OCTINOXATE 2449 mg in 30 mL / OCTOCRYLENE 993 mg in 30 mL / TITANIUM DIOXIDE 1522 mg in 30 mL TOPICAL CREAM [CLE DE PEAU BEAUTE UV PROTECTIVE TINTED DARK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 993 mg once (group E)
Study: 3045295
Drug: Captopril (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6 mg orally)
Study: 3045295
Drug: Saralasin acetate
Normalized name: saralasin acetate
DrugBank: Saralasin (DB06763)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saralasin acetate (50 ng kg‐1 min‐1 intravenous infusion)
Study: 15333400
Drug: Ropivacaine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 20 mg
Study: 29236228
Drug: Ropivacaine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 25 mg
Study: 23719546
Drug: N-acetylcysteine (NAC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC; 20 mg · kg(‐1) · d(‐1))
Study: 18258715
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with paclitaxel plus carboplatin followed by interval debulking surgery and an additional four cycles of postsurgical chemotherapy
Study: 18258715
Drug: Primary debulking
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary debulking surgery (PDS) followed by eight cycles of postsurgical chemotherapy with or without interval debulking surgery
Study: 16466688
Drug: Videoconferencing-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconferencing-based cognitive-behavioral therapy (CBT)
Study: 14587411
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of contrast material (Iomeprol 300 mgI/ml or 350 mgI/ml) only
Study: 14587411
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of contrast material (300 mgI/ml or 350 mgI/ml) flushed with 50 ml of saline solution at a rate of 5 ml/sec
Study: 12141525
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment in infants with RDS
Study: 3324526
Drug: Verapamil (mean,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (mean, 493 +/- 136 mg/day)
Study: 3324526
Drug: Propranolol (mean,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean, 340 +/- 135 mg/day)
Study: 31726490
Drug: Intrapleural infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapleural infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight
Study: 31726490
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight
Study: 27860499
Drug: Insulin LM75/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin LM75/25
Study: 11818027
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy (IORT) with a dose of 12-15 Gy (median 15 Gy) followed by postoperative external radiation therapy (EXRT) with a median total dose of 60 Gy.
Study: 11818027
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with postoperative external radiation therapy (EXRT) alone.
Study: 2376428
Drug: Dextromethorphan-salbutamol combination
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan-salbutamol combination tablet (Redol comp)
Study: 2376428
Drug: Plain dextromethorphan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain dextromethorphan tablet (Extuson)
Study: 14503
Drug: Acebutolol (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (2.0 g total dosage over 48 hours)
Study: 31997647
Drug: Adapted alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted alternating treatments design
Study: 31997647
Drug: Alternative methods
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative methods (e.g., random assignment)
Study: 24843631
Drug: Exenatide once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide once-weekly (EQW)
Study: 21752951
Drug: 1/5 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/5 dose of Meningococcal ACWY polysaccharide (PsACWY)
Study: 19710585
Drug: School-based sore
Normalized name: Sucrets Sore Throat
DrugBank: Dyclonine (DB00645)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: School-based sore throat clinic program with free nurse-observed oral penicillin treatment of group A streptococcal pharyngitis
Study: 12890841
Drug: High-dose bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bevacizumab (10 mg/kg every two weeks)
Study: 12890841
Drug: Low-dose bevacizumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bevacizumab (3 mg/kg every two weeks)
Study: 10199350
Drug: Spinal-cord stimulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal-cord stimulation in addition to best medical treatment
Study: 7766296
Drug: Low-dose OKT3
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose OKT3 (0.5 mg twice daily)
Study: 7766296
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose OKT3 (5 mg daily)
Study: 2279744
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide using 0.025% cream
Study: 7437907
Drug: Pizotifen 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen 2 mg (single oral dose)
Study: 7437907
Drug: Methysergide (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methysergide (dosage not specified)
Study: 7437907
Drug: Bromocriptine 2.5
Normalized name: bromocriptine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 2.5 mg twice daily for 4 days
Study: 7437907
Drug: Pizotifen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen 0.5 mg 3 times daily for 12 days
Study: 28641315
Drug: Sequential regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen: 4 cycles of epirubicin 90 mg/m² followed by 4 cycles of docetaxel 75 mg/m²
Study: 28641315
Drug: Concurrent regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent regimen: 6 cycles of epirubicin 75 mg/m² plus docetaxel 75 mg/m²
Study: 24617000
Drug: SIT (standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT (standardized allergen vaccine)
Study: 16565866
Drug: Supplemental nocturnal
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Supplemental nocturnal oxygen (3 l/min) (n = 16)
Study: 14601199
Drug: 2.5 ml
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml 0.75% ropivacaine (18.75 mg)
Study: 14601199
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml 0.75% ropivacaine (22.5 mg)
Study: 10991865
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of racemic dOTC
Study: 10991865
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of racemic dOTC
Study: 10991865
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of racemic dOTC
Study: 10991865
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of racemic dOTC
Study: 10991865
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg of racemic dOTC
Study: 8854777
Drug: Continuous hepatic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hepatic artery infusion of 5-FU (500 mg x 4 days/week for six weeks from 2 weeks after surgery)
Study: 8854777
Drug: Oral 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral 5-FU from 2 weeks after surgery
Study: 1296454
Drug: IL-2 at
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 at a dose of 3 million IU subcutaneously twice/daily for 6 days/week for 4 weeks
Study: 1296454
Drug: IL-2 once/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 once/daily in the evening
Study: 1296454
Drug: IL-2 once/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 once/daily plus MLT at 10 or at 50 mg/day
Study: 1296454
Drug: IL-2 given
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 given twice/daily
Study: 6084924
Drug: Desogestrel (0.150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel (0.150 mg) plus Ethinyl Estradiol (0.03 mg)
Study: 6084924
Drug: Levonorgestrel (0.150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (0.150 mg) plus Ethinyl Estradiol (0.03 mg)
Study: 26655493
Drug: Low-dose fentanyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fentanyl (1 μg/kg)
Study: 26655493
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl (10 μg/kg)
Study: 24371300
Drug: Oral antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidant therapy (mixed tocopherols 666 IU/d plus α-lipoic acid 600 mg/d)
Study: 22770692
Drug: High thoracic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High thoracic epidural analgesia (HTEA) as a supplement to general anesthesia
Study: 17940111
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone patches
Study: 12792707
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg orally every 8 h)
Study: 12792707
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg on the first day, 100 mg/day thereafter)
Study: 12792707
Drug: Captopril-Aspirin (Captopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril-Aspirin (Captopril on the first day, followed by Aspirin)
Study: 12792707
Drug: Aspirin-Captopril (Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-Captopril (Aspirin on the first day, followed by Captopril)
Study: 17182183
Drug: Nortriptyline (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (25-100 mg)
Study: 1694647
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulphate (20 mg elemental zinc twice daily)
Study: 15279521
Drug: Reduction counseling
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction counseling plus nicotine replacement therapy (NRT) plus brief advice to quit
Study: 11595291
Drug: Cytokines administration
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokines administration with or without therapeutic vaccination in HAART treated patients
Study: 11595291
Drug: Treatment interruption
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment interruption (TI) or drug therapy change from a PI- to a non-nucleoside-based HAART regimen
Study: 11595291
Drug: HAART (Protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART (Protease inhibitor-based)
Study: 9625829
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (lobectomy, sleeve lobectomy, bilobectomy)